Your browser doesn't support javascript.
loading
Successful implementation of a stakeholder engagement program for pharmacoepidemiologic research.
Cromer, Sara J; Steiner, Barbara; York, Cassie; Mastrorilli, Julianna; Lake, Gillian A; Leibowitz, Sherry; Simmons, Leigh; Steppel-Reznik, Jeanne; Low, Greg; Fischer, Michael A; Patorno, Elisabetta; Wexler, Deborah J.
Affiliation
  • Cromer SJ; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Steiner B; Diabetes Unit, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • York C; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Mastrorilli J; Diabetes Unit, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Lake GA; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Leibowitz S; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Simmons L; Hands on Health Therapeutic Massage, Dartmouth, Massachusetts, USA.
  • Steppel-Reznik J; Brookline, MA, USA.
  • Low G; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Fischer MA; Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Patorno E; Division of Endocrinology and Diabetes, Newton-Wellesley Hospital, Boston, Massachusetts, USA.
  • Wexler DJ; Massachusetts General Hospital Physicians Organization, Massachusetts General Hospital, Boston, Massachusetts, USA.
Pharmacoepidemiol Drug Saf ; 33(1): e5727, 2024 Jan.
Article in En | MEDLINE | ID: mdl-37985010
ABSTRACT

PURPOSE:

Rigorously conducted pharmacoepidemiologic research requires methodologically complex study designs and analysis yet evaluates problems of high importance to patients and clinicians. Despite this, participation in and mechanisms for stakeholder engagement in pharmacoepidemiologic research are not well-described. Here, we describe our approach and lessons learned from engaging stakeholders, of varying familiarity with research methods, in a rigorous multi-year pharmacoepidemiologic research program evaluating the comparative effectiveness of diabetes medications.

METHODS:

We recruited 5 patient and 4 clinician stakeholders; each was compensated for their time. Stakeholders received initial formal training in observational research and pharmacoepidemiologic methods sufficient to enable contribution to the research project. After onboarding, stakeholder engagement meetings were held virtually, in the evening, 2-3 times annually. Each was approximately 90 min and focused on 1-2 specific questions about the project, with preparatory materials sent in advance.

RESULTS:

Stakeholder meeting attendance was high (89%-100%), and all stakeholders engaged with the research project, both during and between meetings. Stakeholders reported positive experiences with meetings, satisfaction, and interest in the research project and its findings, and dedication to the success of the project's goals. They affirmed the value of receiving materials to review in advance and the effectiveness of a virtual platform. Their contributions included prioritizing and suggesting research questions, optimizing written evidence briefs for a lay audience, and guidance on broader topics such as research audience and methods of dissemination.

CONCLUSIONS:

Stakeholder engagement in pharmacoepidemiologic research using complex study designs and analysis is feasible, acceptable, and positively impacts the research project.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Diabetes Mellitus / Stakeholder Participation Limits: Humans Language: En Journal: Pharmacoepidemiol Drug Saf Journal subject: EPIDEMIOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2024 Type: Article Affiliation country: United States

Full text: 1 Database: MEDLINE Main subject: Diabetes Mellitus / Stakeholder Participation Limits: Humans Language: En Journal: Pharmacoepidemiol Drug Saf Journal subject: EPIDEMIOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2024 Type: Article Affiliation country: United States